Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis

Activation of Pyroptotic Cell Death Pathways in Cancer: An Alternative Therapeutic Approach

(2019) Kanipandian Nagarajan et al.   Translational Oncology

Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma

(2018) Lei Zhong et al.   INVESTIGATIONAL NEW DRUGS

Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: A systematic review

(2017) Aisha A. Hussein et al.   EUROPEAN JOURNAL OF CANCER

Death by HDAC Inhibition in Synovial Sarcoma Cells

(2017) Aimée N. Laporte et al.   MOLECULAR CANCER THERAPEUTICS

Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells

(2017) Fengshan Li et al.   Molecular Medicine Reports

Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation

(2016) Lianmin Bao et al.   CELL BIOLOGY AND TOXICOLOGY

Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth

(2016) Sung Eun Kim et al.   Nature Nanotechnology

The enhancing effect of genistein on apoptosis induced by trichostatin A in lung cancer cells with wild type p53 genes is associated with upregulation of histone acetyltransferase

(2016) Tzu-Chin Wu et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells

(2015) Xiaofang Sun et al.   HEPATOLOGY

Ferroptosis as a p53-mediated activity during tumour suppression

(2015) Le Jiang et al.   NATURE

Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma

(2015) U Heinicke et al.   ONCOGENE

Epigenetic changes and functional study ofHOXA11in human gastric cancer

(2015) Yingying Cui et al.   Epigenomics

Epigenetic changes in BRCA1-mutated familial breast cancer

(2015) Bradley Downs et al.   Cancer Genetics

Regulation of Ferroptotic Cancer Cell Death by GPX4

(2014) Wan Seok Yang et al.   CELL

The chemopreventive activity of the histone deacetylase inhibitor tributyrin in colon carcinogenesis involves the induction of apoptosis and reduction of DNA damage

(2014) Renato Heidor et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy

(2014) X Li et al.   Cell Death & Disease

Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis

(2014) Nadarajah Vigneswaran et al.   Oral and Maxillofacial Surgery Clinics of North America

NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice

(2013) Alexander Wree et al.   HEPATOLOGY

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

(2012) Scott J. Dixon et al.   CELL

Histone deacetylases and cancer

(2012) Bruna Barneda-Zahonero et al.   Molecular Oncology

Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model

(2012) Deepali Kurundkar et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

The importance of stromal inflammation in squamous cell carcinoma of the tongue

(2011) Lotta Lundqvist et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival

(2011) Stamatios Theocharis et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

HDACs and HDAC inhibitors in colon cancer

(2010) John M. Mariadason   Epigenetics

Prognostic evaluation of oral tongue cancer: Means, markers and perspectives (II)

(2010) Ibrahim O. Bello et al.   ORAL ONCOLOGY

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair

(2010) J.- H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity

(2009) J. Arts et al.   CLINICAL CANCER RESEARCH

Clinical Studies of Histone Deacetylase Inhibitors

(2009) H. M. Prince et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications

(2009) C Scully et al.   ORAL DISEASES

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

(2008) Jennifer S. Carew et al.   CANCER LETTERS

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

Acetylation Is Indispensable for p53 Activation

(2008) Yi Tang et al.   CELL